Skip to main content

Aviado · Research

Longevity Daily

Tuesday, November 17, 2026

Today's Brief

Today's issue is anchored by one of the most exciting Alzheimer's drug results in recent memory: AR1001, a once-daily pill that acts like 'Viagra for the brain,' slowed clinical decline by a third in a Phase 2 trial. A 20-year, 2,800-person ACTIVE Study analysis delivers a genuinely actionable finding: less than 24 hours of computerized speed-of-processing training meaningfully cut dementia diagnoses. Yale researchers confirm that metformin and the Mediterranean diet outperform most supplements at slowing biological aging, and Aviado unpacks why tissue iron deficiency — invisible on standard labs — may be your most overlooked energy drain.

10 stories4 peer-reviewed2 trials1 Aviado original

Cognitive Health & Neuroprotection

Must ReadThe Independent· 2026-11-17

Once-Daily 'Brain Viagra' Pill Slows Alzheimer's Clinical Decline by a Third

AR1001, a once-a-day phosphodiesterase inhibitor developed by South Korean biotech ArioBio, reduced clinical decline in Alzheimer's patients by approximately 33% in a Phase 2 trial presented at the CTAD 2026 conference in Boston. The drug boosts blood flow and cyclic AMP signaling in the brain — a mechanism distinct from the amyloid-clearing approaches of lecanemab or donanemab, meaning it could potentially work alongside those drugs rather than competing with them. Data presented at CTAD suggests the effect was consistent across early-stage patients, though Phase 3 results will be needed to confirm efficacy and safety at scale. If you have a loved one managing early Alzheimer's, AR1001 is worth flagging for your neurologist.

Read more →
Clinical TrialThe New York Times· 2026-11-16

Largest Trial of an Alzheimer's Gamma Wave Headset Delivers Mixed Results

The Phase 3 trial of Cognito Therapeutics' Spectris device — which delivers 40Hz flickering light and sound to stimulate gamma brain waves — did not hit its primary endpoint across the full Alzheimer's patient cohort. Subgroup analyses suggested potential benefit in early-stage patients, but the mixed results raise important questions about which patients, if any, derive meaningful benefit. The finding is a sobering reminder that even biologically plausible, non-invasive interventions face a high evidentiary bar when tested rigorously.

Read more →
New ResearchGlobeNewsWire· 2026-11-16

Less Than 24 Hours of Brain Speed Training Cut Dementia Risk Over 20 Years

A new analysis of the 2,800-person ACTIVE Study — the longest randomized cognitive intervention trial on record — found that speed-of-processing brain training totaling less than 24 hours over three years significantly reduced Alzheimer's Disease and Related Dementia diagnoses across a 20-year follow-up. The analysis identifies reduced processing speed as a key modifiable risk factor for dementia, suggesting the training works by directly targeting this specific neurological vulnerability. The research was presented by Posit Science, maker of the BrainHQ platform that commercializes this training — worth noting, though the underlying ACTIVE Study data is independently peer-reviewed.

Read more →

Supplements & Compounds

New ResearchNutraIngredients· 2026-11-16

Higher Blood DHA Levels Are Linked to an 18% Lower Risk of Frailty

A new study co-authored by Dr. William Harris of OmegaQuant found that people with higher circulating DHA — the long-chain marine omega-3 found in fatty fish, krill, and algae oil — had an 18% lower risk of developing frailty compared to those with lower levels. DHA's anti-inflammatory properties and role in cell membrane integrity likely underpin the association, with particular relevance for muscle and nerve preservation in aging. If you're supplementing with omega-3s, check that your product lists DHA content prominently — many cheaper fish oils are EPA-heavy and may not deliver this benefit.

Read more →
Aviado ResearchAviado Research· 2026-05-04

Why Iron — Not the Supplement You'd Expect — May Be Silently Limiting Your Cellular Energy

Your mitochondria run on iron just as much as CoQ10 or NAD+: iron forms the core of cytochrome complexes and iron-sulfur clusters that power the electron transport chain. The catch is that standard blood tests (CBC) often miss the tissue-level deficiency that actually limits ATP output — meaning you can feel exhausted and underperform while appearing 'normal' on labs. Human trials consistently show iron supplementation improves VO2 max and reduces fatigue within 4–12 weeks in people with low tissue iron, and Aviado's deep dive covers the best-absorbed forms (ferrous bisglycinate and lactoferrin) and why timing and cofactors matter more than simply increasing your dose.

Read the full Aviado analysis →

Research & Papers

Evidence CheckNature Medicine· 2026-11-16

Yale Review of 51 Studies: Metformin and Mediterranean Diet Slow Biological Aging — Most OTC Supplements Don't

A Yale-led review of 51 studies using biological aging clocks — including epigenetic and proteomic measures — found that the Mediterranean diet, TNF inhibitors, and metformin produced measurable reductions in biological age markers. Popular over-the-counter supplements showed little to no detectable effect on these aging clocks by comparison. The finding doesn't mean supplements are useless for health broadly, but it does challenge the narrative that most of them are meaningfully slowing biological aging at the cellular level.

Read more →
New ResearchNews-Medical· 2026-11-16

UC San Diego Identifies Gut Microbiome Signatures of Exceptional Human Longevity

Researchers at UC San Diego mapped how the metabolic activity of the gut microbiome differs in people who reach exceptional longevity, identifying specific microbial pathways associated with long life. When they amplified the same activity using engineered bacteria in animal models, the longevity-linked effects were reproduced — suggesting these microbiome patterns may actively contribute to long life rather than merely correlate with it. Human probiotic applications are a long way off, but this provides one of the clearest mechanistic links yet between gut microbiome activity and exceptional lifespan.

Read more →

Lifestyle & Nutrition

Evidence CheckThe Independent· 2026-11-16

Past 65, a Higher BMI Is Linked to Greater Longevity — Challenging Long-Held Advice

New research suggests standard BMI guidelines may not apply equally across the lifespan: past age 65, a higher BMI is associated with greater longevity rather than reduced health outcomes. This 'obesity paradox' in older adults may reflect that body reserves — including fat mass and muscle — provide a protective buffer against illness, falls, and metabolic stress in later life. If you're an older adult aggressively targeting a 'normal' BMI, this finding is worth discussing with your doctor before making further changes.

Read more →

Industry & Policy

IndustryNutritional Outlook· 2026-11-16

FDA Moves to Formally Legalize NAC as a Dietary Supplement Ingredient

In a 39-page proposed rulemaking, the FDA has moved to reverse its longstanding position that N-acetyl-L-cysteine (NAC) is excluded from the dietary supplement definition under the FD&C Act. If finalized, the rule replaces the agency's existing enforcement discretion policy and gives NAC unambiguous legal standing as a supplement for the first time since 2020. NAC is widely used for liver support, glutathione synthesis, and antioxidant defense — this regulatory clarity would likely expand its availability across mainstream retail channels.

Read more →
IndustryLongevity.Technology· 2026-11-16

Chris Hemsworth Launches AI Longevity Platform Kinsyn, Offering GLP-1s and NAD+ Prescriptions

Chris Hemsworth — who publicly disclosed a genetic predisposition to Alzheimer's and pivoted to intensive health optimization — has launched Kinsyn, an AI-powered platform integrating medical records, wearable data, and licensed provider consultations for personalized longevity therapies including GLP-1s and NAD+ injections. The platform has a Stanford geneticist on its advisory board and aims to make precision longevity medicine broadly accessible. Celebrity-backed health platforms proliferate quickly; Kinsyn's clinical advisory structure and biomarker-driven personalization give it more substance than most.

Read more →